

'Real-World' Exenatide Efficacy Falls Short in Study

BY SHERRY BOSCHERT
San Francisco Bureau

SAN FRANCISCO — The real-world efficacy of exenatide to lower hemoglobin A_{1c} levels in patients with type 2 diabetes may not always match the success seen in clinical trials, a small retrospective study suggests.

Only 12 (40%) of 30 patients with type 2 diabetes who added the incretin mimetic exenatide to ongoing treatment with oral medications or insulin were still taking exenatide 2 years later. For the group as a whole, much of the weight lost after 6 months of exenatide therapy was regained by 2 years, so final weights were not significantly different from baseline weights, the intent-to-treat analysis found.

Much of the weight lost after 6 months of exenatide therapy was regained by 2 years, so final weights were not significantly different from baseline weights.

Hemoglobin A_{1c} (HbA_{1c}) levels did not change significantly for the group as a whole, study investigator Dr. Jennifer A. Loh of Georgetown University, Washington, reported at the annual scientific sessions of the American

Diabetes Association.

A separate comparison found trends toward decreased HbA_{1c} levels in the 15 patients who were taking oral medications plus exenatide, and increased HbA_{1c} levels in the 15 patients using the off-label combination of insulin and exenatide.

Significant decreases in weight were achieved and sustained only in six patients who took exenatide for 2 years and also were on oral medications, not insulin.

"Real-world efficacy is not sustained in all patients; however, there is a small proportion of these patients who did have sustained efficacy in our group," she said. Further research would be helpful to identify the patients most likely to benefit from exenatide therapy, added Dr. Loh. She and coinvestigator Dr. Stephen C. Clement, also of the university, reported no potential conflicts of interest.

Phase III clinical trials have reported significant, long-term efficacy in lowering HbA_{1c} levels and reducing weight in patients with type 2 diabetes. Weight declined by 2.8 kg on average, and HbA_{1c} levels fell by 0.8% in a 30-week randomized, double-blind controlled trial (Diabetes Care 2005;28:1092-100). In three open-label extension studies lasting 82-156 weeks, HbA_{1c} levels decreased by 1.1%-1.3%, and average weight decreased by 4.7-5.3 kg, she noted.

Those open-label studies did not use intent-to-treat analyses, however, and did not include off-label use of insulin. Clinical practices in the studies may not reflect real-world practices, Dr. Loh said.

In the current study, the investigators retrospectively reviewed data on 47 adults who were treated by a single physician and who started exenatide in 2005, shortly after approval of the drug. In all, 17 patients

had incomplete data, including 1 patient who simply refused to be weighed. "This is the real world," Dr. Loh noted.

Of the 30 patients with complete data, 18 (60%) stopped taking exenatide by 2 years. A total of 12 patients stopped because of treatment "failure" and 6 stopped because of side effects.

Patients were moderately obese, with an average body mass index of 35 kg/m². Weight loss on exenatide was significant at 6 and 12 months, but by 2 years weights av-

eraged only 2.09 kg less than at baseline, a loss that was not statistically significant.

HbA_{1c} levels did not change significantly, and averaged 7.7% after 2 years.

The researchers conducted a subanalysis of the 12 patients who stayed on exenatide for 2 years. They found a significant (1.07%) decrease in HbA_{1c} levels, and a significant 4.9-kg loss in weight compared with baseline in the six patients who were taking exenatide and oral medications, but no significant changes were seen in the

six patients on exenatide and insulin. The efficacy seen with exenatide and oral medications in those who continued exenatide therapy mirrored results from clinical trials, she noted.

"This is such a small study," cautioned one of the moderators of the session, Dr. Steven Edelman, director of the diabetes care clinic at the Veterans Affairs San Diego Healthcare System. Previous studies did not include insulin, which makes them difficult to compare, he added. ■



#1 OB/GYN recommended calcium supplement for pregnant patients

The missing link to prenatal health.

90% of women don't get enough calcium in their childbearing years.¹ Even from their prenatal vitamins.²⁻⁸

Prenatal Vitamins don't supply enough calcium. TUMS can help!

Minimum elemental calcium threshold = 1000 mg to 1300 mg²

1200mg

Prenatal vitamin supplements do not deliver the calcium your patients actually require during pregnancy, potentially increasing prenatal risk.²⁻⁸

250mg

0mg

125mg

200mg

200mg

162mg

PreCare®
Prenatal

Natafort®
Prenatal

CitraNatal®
DHA & Rx

Stuart®
Prenatal

Centrum®
Multivitamin

One-A-Day®
Maximum

TUMS® Smoothies
2 tablets twice daily

Milligram values are based on the brand's recommended daily dose

TUMS gives women the vital calcium they need.

- Two TUMS Smoothies Tablets twice daily can provide 1200 mg of elemental calcium.
- The calcium in TUMS® has been shown to help reduce the risk of pre-eclampsia, especially in women with low calcium intake.⁹

Recommend TUMS with every prenatal vitamin.



TUMS
The calcium link to good prenatal health

References: 1. Calcium Recommendations. Available at: http://www.nationaldairycouncil.org/nationaldairycouncil/nutrition/nutrients/calcium_recommendations.pdf. 2. Institute of Medicine. DRI: Dietary Reference Intake for Calcium, Phosphorus, Magnesium, Vitamin D and Fluoride. Washington, DC: National Academy Press; 1997. 3. PreCare Prenatal product labeling. 4. Natafort Prenatal product labeling. 5. CitraNatal RX product labeling. 6. Stuart Prenatal product labeling. 7. Centrum Multivitamin product labeling. 8. One-A-Day Multivitamin product labeling. 9. Hofmeyr, GJ, Atallah, Duley L. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. The Cochrane Library 2006 Syst. Rev 2008;3:CD001059. PreCare is a registered trademark of KV Pharmaceutical Company. Natafort is a registered trademark of Warner Chilcott, PLC. CitraNatal is a registered trademark of Mission Pharmaceutical Company. Stuart is a registered trademark of Integrity Pharmaceutical Corporation. Centrum is a registered trademark of Wyeth Consumer Healthcare. One-A-Day is a registered trademark of Bayer Consumer Healthcare Read and follow label directions. ©2008 GlaxoSmithKline. GSK8-029